Why Five Prime Therapeutics Stock Gained 312% in November

Shares of the clinical-stage cancer specialist Five Prime Therapeutics (NASDAQ:FPRX) gained a stately 312% over the course of November, according to data from S&P Global Market Intelligence. The drugmaker's shares blasted higher last month in response to positive mid-stage trial data for its novel stomach cancer candidate known as bemarituzumab.